Progress, Potential, and Possibilities Podcast / Show

Send us Fan MailENA Respiratory ( https://enarespiratory.com/ ) is a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, including the elderly, those with chronic lung conditions and individuals with occupational risk (e.g. first responders, military or essential services personnel). The company is also developing its innate immune modulators as vaccine adjuvants. ENA Respiratory is based in Melbourne and Sydney, Australia Dr. Ruth Tal-Singer, Ph.D., Medicine Development Leader, ENA Respiratory, is an internationally recognized healthcare leader and clinical scientist with extensive Research and Development experience including recent roles as Vice President of Respiratory Medical Innovation R&D Value Evidence & Outcomes and Senior Fellow at GSK Pharmaceuticals where during her career she led many projects that resulted in new insights, bringing new treatments to the market. She also formerly served as Chief scientific officer and CEO of the COPD Foundation, where she led the patient-centered research, education, and global community outreach advocacy organization focused on the prevention and early diagnosis and treatment of chronic lung diseases. Her vision led to the creation of World Bronchiectasis Day, observed on July 1. Dr. Tal-Singer’s idea resulted in global awareness of the under-researched and under-represented bronchiectasis disease in partnership with 20 other global patient advocacy, academic, and research organizations. As the leader of COPD360Net, the COPD Foundation’s digital health, medical devices, and therapeutics development accelerator network, she championed the partnership between ENA Respiratory and the COPD Foundation and served as a member of its Board of Directors on behalf of the COPD Foundation until March 31, 2023. Dr. Tal-Singer has a proven history of successfully leading international public and private partnerships and non-profit organizations through critical advancements and progress of clinical trials and large observational cohorts. As a researcher, Dr. Tal-Singer has authored 180+ peer-reviewed papers including highly cited scientific publications. She has a Doctor of Philosophy (PhD), Molecular Biology / Microbiology, from University of Pennsylvania, did post-doctoral work at the Wistar Institute, and continues to lecture at the Institute of Translational Medicine and Therapeutics at Penn. Dr. Scott M. White, M.D., Chief Medical Officer, ENA Respiratory, is an infectious diseases physician who has spent over 17 years working in the pharmaceutical and biotech industry. Most recently he served as Vice President Clinical Development for the infectious diseases therapeutic area of Inovio Pharmaceuticals where he was responsible for the clinical development of immunotherapeutic and prophylactic DNA-based vaccines. Prior to this he was a Physician Project Leader for GlaxoSmithKline. In this role he was accountable for several development programs spanning pre-candidate selection through early stage clinical development of assets in the therapeutic areas of infectious diseases, hematology, and dermatology. During this time at GlaxoSmithKline, in collaboration with AstraZeneca, the EU Innovative Medicines Initiative, and medical and scientific leaders throughout Europe, he led the establishment of COMBACTE; a European antibacterial clinical trial network supporting the development of antibiotics targeting resistant organisms.  Dr. White has his M.D. from Pennsylvania State University College, and did an Infectious Diseases Fellowship at University of Pittsburgh School of Medicine. Support the show

Send us Fan MailDr. Marco Quarta, Ph.D. is Co-Founder and CEO of Rubedo Life Sciences ( https://www.rubedolife.com/ ), a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. The company's proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. Dr. Quarta received his doctorate degree in Biotechnology from the University of Bologna and a Ph.D. in Neuroscience from the University of Padua. He completed a post-doc in Aging and Stem cell Biology in the lab of Prof. Thomas Rando at Stanford University and continued his work at Stanford directing a research team at the Center for Tissue Regeneration, Repair, and Restoration at the VA Hospital in Palo Alto, CA. While there, he established a translational program in regenerative medicine. He has over 35 publications and patents in the field of aging, stem cells, regenerative medicine, and rejuvenation. Dr. Quarta also co-founded Wetware Concepts, Young European Biotech Network (YEBN), and Turn Biotechnology, and served as an executive board member of the European Federation of Biotechnologies. He currently sits on the advisory board of the California Institute for Regenerative Medicine (CIRM) Calpoly Bridge program, and the advisory board at the Center for Healthcare Innovation. He is a member of the Paul F Glenn Center for the Biology of Aging Studies at Stanford University, one of the most prestigious institutions supporting the science of aging. Dr. Quarta also serves as CEO and President for the Board of Directors of The Phaedon Institute ( https://www.phaedon.institute/ ), a think-tank organization that operates with the mission of supporting and enabling effective and sustainable growth in the field of aging and longevity sciences. Support the show

Send us Fan MailDr. Peter M. Fleischut, M.D., is Group Senior Vice President and Chief Information and Transformation Officer at NewYork-Presbyterian ( https://www.nyp.org/ )where he oversees the strategic vision and management of enterprise information technology, lab operations, pharmacy operations, innovation, data and analytics, artificial intelligence, telemedicine, and cybersecurity. Dr. Fleischut has led the development of the Hospital’s award-winning digital health services and the implementation of clinical operations at NewYork-Presbyterian David H. Koch Center, a world-class ambulatory care center. In his previous role as Senior Vice President and Chief Transformation Officer, he focused on creating a single electronic medical record across NewYork-Presbyterian and its affiliated medical schools, Weill Cornell Medicine and Columbia University Vagelos College of Physicians and Surgeons. Dr. Fleischut also led efforts to standardize care across NYP’s ten hospitals and hundreds of clinics and doctor practices, and oversaw all aspects of Graduate Medical Education (GME) for programs across the NYP enterprise. Joining NewYork-Presbyterian/Weill Cornell in 2006, Dr. Fleischut previously served as Medical Director of Operating Rooms, Deputy Quality Patient Safety Officer, founding Director of the Center for Perioperative Outcomes, Vice Chairman, Chief Medical Information Officer, Chief Innovation Officer and Chief Medical Operating Officer. In 2016, Dr. Fleischut became Vice Chair of the Department of Anesthesiology at Weill Cornell Medical College, where he is an Assistant Professor of Anesthesiology. He is a graduate of Jefferson Medical College and the Wharton Program for Working Professionals at the University of Pennsylvania. Dr. Fleischut has received numerous awards and honors, including NewYork-Presbyterian’s Physician of the Year, Modern Healthcare Up and Comers, Becker’s Hospital Review 40 under 40, and the American Telehealth Association President’s Award. NewYork-Presbyterian is one of the nation’s most comprehensive, integrated academic health care delivery systems, dedicated to providing the highest quality, most compassionate care and service to patients in the New York metropolitan area, nationally, and throughout the globe. In collaboration with two renowned medical schools, Weill Cornell Medicine and Columbia University Vagelos College of Physicians and Surgeons, NewYork-Presbyterian is consistently recognized as a leader in medical education, groundbreaking research, and innovative, patient-centered clinical care. Support the show

Send us Fan MailDr. George R. Dodge, Ph.D. is CEO & Co-Founder of Mechano-Therapeutics LLC ( https://mechano-therapeutics.com/ ), a biotechnology company spun out from his lab, and the labs of his partners Dr. Rob Mauck and Dr. Daeyeon Lee, at the University of Pennsylvania, specializing in microcapsule development using proprietary microfluidics for drug encapsulation, with a mission to revolutionize musculoskeletal health using an innovative platform technology to enhance delivery of therapeutics for improving patient outcomes. Dr. Dodge recently served on the faculty of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania; as Director, Philadelphia VA Shared Instrument Core; and Director, Translational Musculoskeletal Research Center, Philadelphia Crescenz Veterans Administration Medical Center, Department of Veteran Affairs. Dr. Dodge has a B.S. (Biology) from Asbury College, a B.S. (Biology and Health Science / Public Health) from State University of New York, a Ph.D. (Biochemistry and Immunology) from McGill University, and did Post-Graduate work in Molecular and Cell Biology, at Thomas Jefferson University Department of Pathology and Cell Biology. Dr. Dodge is an established investigator with a career long commitment to translational musculoskeletal research and in particular research focused on cartilage and chondrocyte biology, extracellular matrix and research related to osteoarthritis. Support the show

Send us Fan MailDr. Majid Fotuhi, M.D., Ph.D. ( https://neurogrow.com/about-us/dr-majid-fotuhi-md-phd/ ) is the Medical Director of NeuroGrow Brain Fitness Center, a neurology practice dedicated for treating patients with concussion, memory loss, or attention deficit disorder. He is also an affiliate staff at Johns Hopkins Medicine ( https://www.hopkinsmedicine.org/profiles/details/majid-fotuhi ) and teaches medical students at Harvard Medical School. He has been an active member of the American Academy of Neurology, American Medical Association, International Brain Research Organization, and Society for Neuroscience. Dr. Fotuhi received his MD degree (cum laude) from Harvard Medical School, as a member of the Harvard-MIT Division of Health Sciences and Technology (HST) and his doctoral PhD degree in Neuroscience from Johns Hopkins University School of Medicine. Dr. Fotuhi’s initial clinical research at Johns Hopkins focused on basic brain neurochemistry and on finding effective ways to prevent dementia. More specifically, he worked on longitudinal studies to determine the beneficial role of a combination of vitamins and natural supplements along with non-steroidal anti-inflammatory drugs (NSAID) in maintaining cognitive function and brain health. His current research focuses on designing multi-disciplinary treatment programs for patients with memory loss and/or post-concussive syndrome. He has published his research findings in Brain Research, Journal of Neuroscience, the Lancet, Nature, Neurology, Neuron, and Proceedings of National Academy of Science. Dr. Fotuhi has dedicated much of his time to educating the public about memory, aging, and concussion. In his book, The Memory Cure: How to Protect Your Brain Against Memory Loss and Alzheimer's Disease, he provides clear and concise information about how to prevent dementia. His second book, entitled The New York Times Puzzles to Keep Your Brain Young: The 6 Step Age Defying Program, was released in January 2008. His most recent book, Boost Your Brain, teaches people how they can grow the size of their hippocampus. He has had two PBS programs, entitled “Conquering Memory Loss” and “Fight Alzheimer’s Early.” He has been interviewed by more than 50 media outlets including ABC News, CTV, CBS, TODAY show, Montel show, Fox News, Dr. Oz show, Discovery Channel, The Boston Globe, USA Today, Health magazine, Ladies’ Home Journal, Forbes, BusinessWeek, The Chicago Tribune, The Washington Post, The Wall Street Journal, The Montreal Gazette, and The Times (London). Dr. Fotuhi has taken a leadership role in medical education as well. He has received numerous awards for his innovative and dynamic teaching style. He is one of the most popular instructors at Harvard Medical School, where he designed and helped to build two 5O foot tall brain models for his students in neuroanatomy classes. He won the distinguished teaching award from the American Academy of Neurology in 2001. He has presented academic lectures as the honorary visiting professor in Canada, Egypt, China, Israel, and Japan; he also had the honor of presenting a lecture at a United Nations meeting in New York in September 2010 and at the legislative briefings for the house and senate in Maryland in February 2015. Support the show

Send us Fan MailMr. Benson Kanyembo is Law Enforcement Advisor, Conservation South Luangwa ( https://cslzambia.org/ ), an organization which works in partnership with Zambia’s Department of National Parks and Wildlife (DNPW) on the frontline of wildlife conservation and human-wildlife coexistence in the South Luangwa Valley. The organization is focused on protecting the 1,400,000 hectares of largely intact wilderness in eastern Zambia that make up the South Luangwa National Park and the surrounding Upper and Lower Lupande game management areas. The Luangwa Valley is home to over 60 species of mammals and 450 species of birds. Species include the unique Crawshay’s zebra, Cookson’s wildebeest, and a geographically isolated population of Luangwa giraffe (G. t. thornicrofti), a subspecies of Masai giraffe. The Valley is also known for its high densities of lion, leopard and wild dog, and it remains a stronghold for elephants in Zambia. Born in Kitwe, the son of a policeman, Mr. Kanyembo grew up with an understanding of the importance of good law enforcement and has devoted over 20 years of his life to protecting Zambia’s wildlife for future generations, including his own four daughters. In 1994, Mr. Kanyembo started his career in wildlife enforcement as a village scout in North Luangwa. In 2000, after the formation of ZAWA (Zambian Wildlife Authority) he became a community scout before rising to the rank of Senior Wildlife Police Officer and was in charge of the training of all scouts and transferred to South Luangwa in 2008. In 2009, Mr. Kanyembo joined CSL as Operations Manager, and during the restructuring in 2018 was promoted to Law Enforcement Advisor. He leads all CSL anti-poaching law enforcement and wildlife rescue operations either in the field or from his control room in collaboration with DNPW. He has facilitated the growth and development of the anti-poaching unit from 30 to 92 scouts. In 2019, Mr. Kanyembo's commitment to conservation in Africa was recognized on the global stage, when he was awarded the TUSK Wildlife Ranger Award in London by Tusk’s Royal Patron HRH The Duke of Cambridge, Prince William of Wales. Support the show

Send us Fan MailDr. Grzegorz (Greg) Ombach, Ph.D. ( https://councils.forbes.com/profile/Greg-Ombach-Head-Disruptive-R-T-Senior-Vice-President-Airbus/b60db4cb-0b87-48cb-a3a0-41068d3d05ab ) is Head of Disruptive R&T ( https://www.airbus.com/en/innovation/disruptive-concepts ) and Senior Vice President, at Airbus, the multinational aerospace corporation, where he is passionate about managing technological innovation from an idea to broad market adoption, and his combination of technology, leadership and commercial expertise together with a truly global outlook, having worked across Europe, the USA and China, puts him in a solid position to drive international market success for high-tech innovations. As a Head of Disruptive R&T, Dr. Ombach shapes Airbus's ability to be the global leader in innovation and future technologies across all Airbus divisions and he works very closely with all businesses and divisions globally. Prior to this role, when Dr. Ombach served as Executive Vice President, Head of Battery Systems Business and Group Strategy and Innovation at Dräxlmaier, he was responsible for the strategy for the business and led the entire product commercialization, from the initial concept to high volume production of cutting-edge technology in a premium market for the automotive sector, including the first high-volume production of an 800V battery system for the Porsche Taycan. Earlier, Dr. Ombach worked at Qualcomm as a Global Vice President and General Manager of a breakthrough automotive technology licensing business and also gained experience from Siemens VDO, Continental and Brose. Dr. Ombach holds a Ph.D. in Electrical Engineering from the Silesian University of Technology, Poland and a Certificate in Global Management from INSEAD, The Business School for the World. He has also been awarded Guest Professorship at the Zhejiang University in China. Support the show

Send us Fan MailDr. Lesley Ogilvie, Ph.D. is Director, Global AMR R&D Hub Secretariat ( https://globalamrhub.org/about/global-amr-rd-hub-secretariat/ ), part of a global partnership focused on addressing challenges and improving coordination and collaboration in Global Antimicrobial Resistance R&D using a One Health approach. Dr. Ogilvie joined the Global AMR R&D Hub in February 2021, hoping to combine scientific insight with targeted action to help combat the silent pandemic of AMR, following over ten years-experience working in academia as a researcher and lecturer in Microbial Ecogenomics, applying molecular and bioinformatics techniques to tackle questions regarding the human gut microbiome/virome in health and disease. Dr. Ogilvie has a BSc (Hons) in Ecology from University of Dundee, UK.; an MSc in Marine Resource Development and Protection from Heriot-Watt University, Edinburgh, UK; a Ph.D. in Environmental Sciences from University of East Anglia; and did Postdoctoral work at the Max Planck Institute for Molecular Genetics. Support the show

Send us Fan MailAdvitya Gemawat ( https://www.microsoft.com/en-us/research/people/agemawat/ ) is a Machine Learning Research Engineer who currently works in the Responsible AI (RAI) team as part of the Azure Machine Learning (AML) and Azure AI Studio product lines, in the Azure AI Platform org. Prior to the RAI team, he was part of the 4th cohort of the Microsoft AI Development Acceleration Program (MAIDAP), where he worked with Azure Quality, Microsoft’s Gray Systems Lab (GSL), Azure Edge & Platform, and Azure Machine Learning (AML). His research experience is at the intersection of Machine Learning & Scalable Systems. His work with GSL was identified as the Microsoft Global Hackathon Executive Challenge 2022 Winner and recipient of the Best Demonstration Award at VLDB 2022. His work with the AML team on expanding the RAI Dashboard to support Object Detection models was released in Public Preview at Microsoft Build 2023. Prior to Microsoft, Advitya graduated from UC San Diego with a Data Science major, where he contributed to Project Cerebro (a Layered Data Platform for scalable Deep Learning) and was advised by Professor Arun Kumar. There, his research won the 2021 ACM SIGMOD Student Research Abstract Competition and the Best Project Award as part of UCSD’s Halıcıoğlu Data Science Institute (HDSI) Undergraduate Scholarship Program HDSI Scholarship Program. As part of an internship with VMware, his work on Massively Parallel Automated Model Building for Deep Learning was included in Apache MADlib 1.18.0 release. Opinions expressed in the video solely reflect Advitya’s views and not the views of his employer. Follow Advitya on the handles below: LinkedIn: linkedin.com/in/agemawat YouTube: youtube.com/@AdvityaGemawat Microsoft Research: microsoft.com/research/people/agemawat Support the show

Send us Fan MailDr. Joni L. Rutter, Ph.D., ( https://ncats.nih.gov/director/bio ) is the Director of the National Center for Advancing Translational Sciences ( NCATS - https://ncats.nih.gov/ ) at the U.S. National Institutes of Health (NIH) where she oversees the planning and execution of the Center’s complex, multifaceted programs that aim to overcome scientific and operational barriers impeding the development and delivery of new treatments and other health solutions. Under her direction, NCATS supports innovative tools and strategies to make each step in the translational process more effective and efficient, thus speeding research across a range of diseases, with a particular focus on rare diseases. By advancing the science of translation, NCATS helps turn promising research discoveries into real-world applications that improve people’s health. The NCATS Strategic Plan can be found at - https://ncats.nih.gov/strategicplan In her previous role as the NCATS deputy director, Dr. Rutter collaborated with colleagues from government, academia, industry and nonprofit patient organizations to establish robust interactions with NCATS programs. Prior to joining NCATS, Dr. Rutter served as the director of scientific programs within the All of Us Research Program, where she led the scientific programmatic development and implementation efforts to build a national research cohort of at least 1 million U.S. participants to advance precision medicine. During her time at NIH, she also has led the Division of Neuroscience and Behavior at the National Institute on Drug Abuse (NIDA). In this role, she developed and coordinated research on basic and clinical neuroscience, brain and behavioral development, genetics, epigenetics, computational neuroscience, bioinformatics, and drug discovery. Dr. Rutter also coordinated the NIDA Genetics Consortium and biospecimen repository. Throughout her career, Dr. Rutter has earned an international reputation for her diverse and unique expertise via her journal publications and speaking engagements, and she has received several scientific achievement awards, including the 2022 Rare Disease Legislative Advocates–RareVoice Award for Federal Advocacy and the 2022 FedHealthIT–Women in Leadership Impact Award. Dr. Rutter received her Ph.D. from the Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, New Hampshire, and completed a fellowship at NCI within the Division of Cancer Epidemiology and Genetics. Support the show